Lotus Returns with New Strength and the FDA Approval to Compete with Sapien3 and CoreValve Evolut R

After reports of some serious adverse events with first-generation Lotus, the device was pulled off the market—but it was not meant to be left in oblivion. Now, it is back, renewed and with the approval of the United States Food and Drug Administration (FDA), to compete directly with the two market leaders (Sapien and CoreValve), which were the only devices approved for the US market so far.

REPRISE III: Leak paravalvular y necesidad de marcapasos con LotusStarting yesterday, there are three percutaneous valves available in the US market; each embodies a different concept and presents advantages and disadvantages. This can be seen as a competition among these devices, but, actually, they will most likely end up supplementing each other. Our responsibility is to find the most appropriate valve for each patient.

 

The FDA has just approved the transcatheter aortic valve replacement system LOTUS Edge for patients at high surgical risk.


Read also: REPRISE III: Lotus and CoreValve Compared in High-Risk or Inoperable Patients.


The FDA decision is supported by the results of the REPRISE III trial, which included the first-generation device and also patients who received the Lotus Edge valve.

 

REPRISE III outcomes were presented at EuroPCR 2017 and showed that the Lotus system was non-inferior to the results of a population receiving both first- and second-generation CoreValve (the latter, Evolut R).

 

Lotus criticism focused on its high rates of need for pacemaker, a problem somewhat solved through a modification to the original design, a change known as “depth guard.” This prevents excessively deep implantations and limits interaction with the outflow tract.


Read also: Lotus Valve in Real Life Patients: the near total lack of leaks is its greatest strength.


The REPRISE III 2-year follow-up (recently published) confirmed the first outcomes for the only valve in the market that allows for full delivery, function assessment, and (in case of unsatisfactory results, such as leak, block, etc.) full recapture, so as to optimize results as much as possible.

 

Patient enrollment for REPRISE IV, including Lotus Edge intermediate-risk patients, started early this year.

 

FDA approval might indirectly increase the use of cerebral protection devices during the procedure, since Boston bought the rights to the Sentinel device last year and there is much speculation about the valve and the cerebral protection device being released for sale as a combined package.

 

Original title: Boston Scientific Receives FDA Approval for LOTUS Edge Aortic Valve System. Published on: April 23, 2019. Accessed on: April 24, 2019.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....